Long-term antihypertensve effects with chronic administration of isradipine controlled release

Current Therapeutic Research - Clinical and Experimental

Volumn 58, Issue 1, 1997, Pages 1-9

  Chrysant, Steven G ^a   Cohen, Michael ^b  

^a UNIVERSITY OF OKLAHOMA   (United States)

^b Sandoz Pharma Ltd   (Switzerland)

Author keywords

calcium channel blocker; diuretic; hypertension; isradipine controlled release

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; DIHYDROPYRIDINE DERIVATIVE; HYDROCHLOROTHIAZIDE; ISRADIPINE; PLACEBO;

ADULT; AGED; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; EDEMA; FATIGUE; FEMALE; HEADACHE; HEART RATE; HUMAN; HYPERTENSION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; METABOLISM; PRIORITY JOURNAL; SITTING; SYSTOLIC BLOOD PRESSURE; VERTIGO;

EID: 0031037177     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-393X(97)80071-9     Document Type: Article

References (26)

1. Frishman WH. Current status of calcium channel blockers. Curr Probl Cardiol. 1994;19: 637-688.
2. Ram CVS. Calcium antagonists as antihypertensive agents are effective in all age groups. J Hypertens. 1987;5(Suppl 4):S115-S118.
3. Trost BN, Weidman P. Effects of calcium antagonists on glucose homeostasis and serum lipids in non-diabetic and diabetic subjects: A review. J Hypertens. 1987;5(Suppl 4):S81-S104.
4. VanBreemen C, Lukeman S, Cauvin C. A theoretic consideration on the use of calcium antagonists in the treatment of hypertension. Am J Cardiol. 1984;77(Suppl 4A):26-30.
5. Reams GP, Hamory A, Lau A, Bauer JH. Effect of nifedipine on renal function in patients with essential hypertension. Hypertension. 1988;11:452-456.
6. Epstein M. Calcium antagonists and renal protection: Current status and future perspectives. Arch Intern Med. 1992;152:1573-1584.
7. Psaty BM, Heckbert SR, Koepsell TD, et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA. 1995;274:620-625.
8. Furberg CD, Psaty BM. Calcium antagonists: Not appropriate as first line antihypertensive agents. Am J Hypertens. 1996;9:122-125.
9. Ruzicka M, Leenen FHH. Relevance of 24 H blood pressure profile and sympathetic activity for outcome on short-versus long-acting, 1, 4-dihydropyridines. Am J Hypertens. 1996;9:86-94.
10. Frohlich ED, McLoughlin MJ, Losen CJ, et al. Hemodynamic comparison of two nifedipine formulations in patients with essential hypertension. Am J Cardiol. 1991;68:1346-1350.
11. Thadani U, Zellner A, Glasser S, et al. Double-blind, dose-response, placebo-controlled multicenter study of nisoldipine: A new second-generation calcium channel blocker in angina pectoris. Circulation. 1991;84:2398-2408.
12. Kloner RA, Sowers JR, DiBona GF, et al. The incidence of myocardial infarction in patients receiving long-acting calcium channel blockers as monotherapy for hypertension. J Am Coll Cardiol. 1996;27:177A. Abstract.
13. Epstein M. Calcium antagonists: Still appropriate as first line antihypertensive agents. Am J Hypertens. 1996;9:110-121.
14. Chrysant SG, Cohen M. Sustained blood pressure control with controlled-release isradipine (isradipine-CR). J Clin Pharmacol. 1995;35:239-243.
15. Data on file, Sandoz Research Institute, East Hanover, New Jersey, 1995.
16. Frishman WH, Garofalo JL, Rothschild A, et al. The nifedipine gastrointestinal therapeutic system in the treatment of hypertension. Am J Cardiol. 1989;64:65F-69F.
17. Miller H. Isradipine: Overall clinical experience in hypertension in the United States. J Cardiovasc Pharmacol. 1990;15(Suppl 1):S60-S64.
18. Bauer JH, Sunderrajan S, Reams G. Effects of calcium entry blockers on renin-angiotension-aldosterone system, renal function, and hemodynamics, salt and water excretion and body fluid composition. Am J Cardiol. 1985;56:62H-67H.
19. Luft FC, Aronoff G, Sloan RS, et al. Calcium channel blockade with nitrendipine. Hypertension. 1985;7:438-442.
20. Krusell LR, Jespersen LT, Schmitz A, et al. Repetitive natriuresis and blood pressure: Long term calcium blockade with isradipine. Hypertension. 1987;10:577-581.
21. Sunderrajan S, Reams G, Bauer JH. Renal effects of diltiazem. Hypertension. 1986;8: 238-242.
22. Hughes GS, Cowart TD, Dexmann MJ, Conradi EC. Verapamil-induced natriuretic and diuretic effects: Dependency on sodium intake. Clin Pharmacol Ther. 1988;44:400-407.
23. Chrysant SG, Chrysant C, Trus J, Hitchcock A. Antihypertensive effectiveness of amlodipine in combination with hydrochlorothiazide. Am J Hypertens. 1989;2:537-541.
24. Holzgreve H, Distler A, Michaelis J, et al. Verapamil versus hydrochlorothiazide in the treatment of hypertension: Results of long term double-blind comparative trial. BMJ. 1989;299:881-886.
25. Chrysant SG, Fox AAL, Stimpel M. Comparison of moexipril, a new ACE inhibitor, to verapamil-SR as add-on therapy to low dose hydrochlorothiazide in hypertensive patients. Am J Hypertens. 1995;8:418-421.
26. Stein GH, Matthews K, Bannatyne E, et al. Long-term lipid profile with isradipine and hydrochlorothiazide treatment in elderly hypertensive patients. J Cardiovasc Pharmacol. 1990;15(Suppl 1):S90-S92.